This episode explores emerging evidence that high-dose tirzepatide may reduce more than appetite and food noise in some people. Mikki breaks down a new case series involving three women who experienced anhedonia, a loss of motivation or interest in previously rewarding activities, despite achieving substantial weight loss. She explains the difference between “wanting” and “liking,” how GLP-1 medications may influence dopamine reward pathways, and why symptoms can feel different from depression or early medication side effects. The cases suggest that dose reduction may restore motivation without necessarily compromising weight-loss maintenance. While three cases cannot establish causation or prevalence, the findings highlight the importance of monitoring exercise, hobbies, social engagement, and overall enjoyment alongside weight, appetite, and gastrointestinal symptoms.

Topics Covered

What anhedonia is and how it differs from depression
Three cases involving high-dose tirzepatide
The potential role of dopamine and reward pathways
Why dose reduction improved symptoms in these cases
Practical considerations for patients and prescribers

Contact Mikki:
https://mikkiwilliden.com/
https://www.facebook.com/mikkiwillidennutrition
https://www.instagram.com/mikkiwilliden/
https://linktr.ee/mikkiwilliden
NZ listeners - save 10% off Calocurb by using the code Mikkipedia10 at www.calocurb.co.nz
Save 20% on all Nuzest Products WORLDWIDE with the code MIKKI at www.nuzest.co.nz, www.nuzest.com.au or www.nuzest.com
Curranz supplement: MIKKI saves you 25% at www.curranz.co.nz or www.curranz.co.uk off your first order